Abstract
BackgroundActivating the innate immune pathway of stimulator of interferon genes (STING) can elicit potent anti-tumor immunity via the production of type-I interferons (IFN-I). However, cyclic-dinucleotide (CDN) STING agonists have undesirable...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have